NewcelX appoints diabetes researcher Camillo Ricordi to scientific advisory board

NewcelX Ltd.

NewcelX Ltd.

NCEL

0.00
  • NewcelX appointed Camillo Ricordi to its Scientific Advisory Board as it advances its Type 1 diabetes cell-therapy program.
  • Ricordi is chief of the Division of Cellular Transplantation at the University of Miami Miller School of Medicine.
  • He is director of the Cell Transplant and NABTU Regenerative Medicine Center, director emeritus of the Diabetes Research Institute.
  • NewcelX highlighted his work in beta-cell replacement, islet transplantation, 1,250 publications, 64,000 citations, h-index 123.
  • Ricordi will advise clinical translation of the company’s biologic replacement strategy, support collaboration with Eledon Pharmaceuticals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080915PRIMZONEFULLFEED9758526) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.